Fmr LLC Bio Atla, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, Fmr LLC holds 51,643 shares of BCAB stock, worth $108,450. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,643

Previous 3,373 1431.07%

Holding current value

$108,450

Previous $11,000 536.36%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.37 - $3.92 $66,129 - $189,218	48,270 Added 1431.07%	51,643 $70,000
Q1 2024 May 13, 2024	BUY	$1.88 - $3.46 $537 - $989	286 Added 9.26%	3,373 $11,000
Q4 2023 Feb 13, 2024	BUY	$1.27 - $3.18 $300 - $753	237 Added 8.32%	3,087 $7,000
Q3 2023 Nov 13, 2023	BUY	$1.7 - $3.07 $1,667 - $3,011	981 Added 52.49%	2,850 $4,000
Q2 2023 Aug 11, 2023	SELL	$2.83 - $3.87 $5,934 - $8,115	-2,097 Reduced 52.87%	1,869 $5,000
Q1 2023 May 11, 2023	BUY	$2.3 - $8.25 $5,975 - $21,433	2,598 Added 189.91%	3,966 $10,000
Q4 2022 Feb 13, 2023	SELL	$6.29 - $11.01 $110,943 - $194,194	-17,638 Reduced 92.8%	1,368 $11,000
Q3 2022 Nov 10, 2022	SELL	$2.94 - $11.87 $869,816 - $3.51 Million	-295,856 Reduced 93.96%	19,006 $146,000
Q2 2022 Aug 12, 2022	SELL	$2.13 - $5.38 $5.55 Million - $14 Million	-2,604,601 Reduced 89.22%	314,862 $897,000
Q1 2022 May 13, 2022	SELL	$4.38 - $18.78 $4.39 Million - $18.8 Million	-1,001,209 Reduced 25.54%	2,919,463 $14.6 Million
Q4 2021 Feb 14, 2022	SELL	$19.0 - $30.95 $16.8 Million - $27.4 Million	-883,731 Reduced 18.39%	3,920,672 $77 Million
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $1.69 Million - $2.51 Million	57,454 Added 1.21%	4,804,403 $0
Q2 2021 Aug 13, 2021	BUY	$38.07 - $56.17 $181 Million - $267 Million	4,746,949 New	4,746,949 $0

Others Institutions Holding BCAB

# of Institutions

Shares Held

22.1M

Call Options Held

10.7K

Put Options Held

7.4K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $76.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account